Abstract
objective: To report preliminary results of a cutting edge extreme hypofractionated treatment with concomitant boost to the dominant lesion for patients with early stage prostate cancer (PCa). methods: AIRC-IG-13218 is a prospective Phase II trial started in June 2015. Patients with low and intermediate risk PCa who met the inclusion criteria underwent extreme hypofractionated radiotherapy to the prostate (36.25 Gy in 5 fractions) and a simultaneous integrated boost to the dominant intraprostatic lesion (DIL) to 37.5 Gy. The DIL was identified by a multiparamentric MRI (mpMRI) co-registered with planning CT. Toxicity was assessed according to CTCAE v4.0 and RTOG/EORTC criteria. The preliminary evaluation of the first 13 patients was required to confirm the feasibility of the treatment before completing the enrollment of 65 patients. results: The first 13 patients completed the treatment between June 2015 and February 2016. With a median clinical follow-up of 17 months (range 11-26), no Grade 3 or 4 early toxicity was reported. Conclusions: Our preliminary data about early toxicity of an extreme hypofractionated schedule with concomitant boost on the DIL are encouraging. The higher number of patients expected for the trial and a longer follow-up are needed to confirm these results.
| Original language | English |
|---|---|
| Article number | 20160725 |
| Journal | British Journal of Radiology |
| Volume | 91 |
| Issue number | 1089 |
| DOIs | |
| Publication status | Published - Jan 1 2018 |
Fingerprint
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion : Ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218. / Timon, Giorgia; Ciardo, Delia; Bazani, Alessia; Marvaso, Giulia; Riva, Giulia; Volpe, Stefania; Rojas, Damaris P.; Renne, Giuseppe; Petralia, Giuseppe; Zerini, Dario; Fodor, Cristiana; Dicuonzo, Samantha; Maestri, Davide; Pansini, Floriana; Cambria, Raffaella; Cattani, Federica; Golino, Federica; Scroffi, Valerio; De Lorenzo, Daniela; De Cobelli, Ottavio; Orecchia, Roberto; Jereczek-Fossa, Barbara Alicja.
In: British Journal of Radiology, Vol. 91, No. 1089, 20160725, 01.01.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion
T2 - Ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218
AU - Timon, Giorgia
AU - Ciardo, Delia
AU - Bazani, Alessia
AU - Marvaso, Giulia
AU - Riva, Giulia
AU - Volpe, Stefania
AU - Rojas, Damaris P.
AU - Renne, Giuseppe
AU - Petralia, Giuseppe
AU - Zerini, Dario
AU - Fodor, Cristiana
AU - Dicuonzo, Samantha
AU - Maestri, Davide
AU - Pansini, Floriana
AU - Cambria, Raffaella
AU - Cattani, Federica
AU - Golino, Federica
AU - Scroffi, Valerio
AU - De Lorenzo, Daniela
AU - De Cobelli, Ottavio
AU - Orecchia, Roberto
AU - Jereczek-Fossa, Barbara Alicja
PY - 2018/1/1
Y1 - 2018/1/1
N2 - objective: To report preliminary results of a cutting edge extreme hypofractionated treatment with concomitant boost to the dominant lesion for patients with early stage prostate cancer (PCa). methods: AIRC-IG-13218 is a prospective Phase II trial started in June 2015. Patients with low and intermediate risk PCa who met the inclusion criteria underwent extreme hypofractionated radiotherapy to the prostate (36.25 Gy in 5 fractions) and a simultaneous integrated boost to the dominant intraprostatic lesion (DIL) to 37.5 Gy. The DIL was identified by a multiparamentric MRI (mpMRI) co-registered with planning CT. Toxicity was assessed according to CTCAE v4.0 and RTOG/EORTC criteria. The preliminary evaluation of the first 13 patients was required to confirm the feasibility of the treatment before completing the enrollment of 65 patients. results: The first 13 patients completed the treatment between June 2015 and February 2016. With a median clinical follow-up of 17 months (range 11-26), no Grade 3 or 4 early toxicity was reported. Conclusions: Our preliminary data about early toxicity of an extreme hypofractionated schedule with concomitant boost on the DIL are encouraging. The higher number of patients expected for the trial and a longer follow-up are needed to confirm these results.
AB - objective: To report preliminary results of a cutting edge extreme hypofractionated treatment with concomitant boost to the dominant lesion for patients with early stage prostate cancer (PCa). methods: AIRC-IG-13218 is a prospective Phase II trial started in June 2015. Patients with low and intermediate risk PCa who met the inclusion criteria underwent extreme hypofractionated radiotherapy to the prostate (36.25 Gy in 5 fractions) and a simultaneous integrated boost to the dominant intraprostatic lesion (DIL) to 37.5 Gy. The DIL was identified by a multiparamentric MRI (mpMRI) co-registered with planning CT. Toxicity was assessed according to CTCAE v4.0 and RTOG/EORTC criteria. The preliminary evaluation of the first 13 patients was required to confirm the feasibility of the treatment before completing the enrollment of 65 patients. results: The first 13 patients completed the treatment between June 2015 and February 2016. With a median clinical follow-up of 17 months (range 11-26), no Grade 3 or 4 early toxicity was reported. Conclusions: Our preliminary data about early toxicity of an extreme hypofractionated schedule with concomitant boost on the DIL are encouraging. The higher number of patients expected for the trial and a longer follow-up are needed to confirm these results.
UR - http://www.scopus.com/inward/record.url?scp=85052588610&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052588610&partnerID=8YFLogxK
U2 - 10.1259/bjr.20160725
DO - 10.1259/bjr.20160725
M3 - Article
AN - SCOPUS:85052588610
VL - 91
JO - British Journal of Radiology
JF - British Journal of Radiology
SN - 0007-1285
IS - 1089
M1 - 20160725
ER -